Still, though to a lesser extent compared to PSP, this same CpG has shown concordant direction of effect in the FTLD2m dataset (FTLD vs. controls, delta-beta = -7.9%, nominal p-value = 0.003), and in all its individual subtype comparisons (FTLD-Tau MAPT mutants vs. controls, FTLD-TDP C9orf72 mutants and GRN mutants vs. controls, Table 1). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.